UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

Annals of oncology, 2010-11, Vol.21 (11), p.2227-2232

2010

Link zum Volltext

Verfügbarkeit prüfen

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

British journal of cancer, 2004-08, Vol.91 (3), p.482-488

2004

Link zum Volltext

Verfügbarkeit prüfen

Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2937-2945

2005

Link zum Volltext

Verfügbarkeit prüfen

Alternate Paclitaxel-Gemcitabine and Paclitaxel-Vinorelbine Biweekly Administration in Non-small Cell Lung Cancer Patients: a Phase II Study

Anticancer research, 2006-03, Vol.26 (2B), p.1397-1402

2006

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

Lung cancer (Amsterdam, Netherlands), 2001-05, Vol.32 (2), p.179-187

2001

Link zum Volltext

Verfügbarkeit prüfen

Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Community-Acquired Pneumonia: The MOTIV Study—A Randomized Clinical Trial

Clinical infectious diseases, 2008-05, Vol.46 (10), p.1499-1509

2008

Link zum Volltext

Verfügbarkeit prüfen

6599 POSTER Comparison of cisplatin–paclitaxel combination versus cisplatinetoposide as first line chemotherapy in SCLC

European journal of cancer supplements, 2007, Vol.5 (4), p.388-388

2007

Link zum Volltext

Verfügbarkeit prüfen

Alternative administration of paclitaxel-gemcitabine and paclitaxel-vinorelbine as first line treatment in NSCLC patients. A phase II study

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.7319-7319

2005

Link zum Volltext

Verfügbarkeit prüfen

HLA antigens in diabetics with calcified shoulder periarthritis (CSP)

Clinical and experimental rheumatology, 1986-10, Vol.4 (4), p.351

1986

Link zum Volltext

Verfügbarkeit prüfen

The sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study

European journal of cancer (1990), 2001-04, Vol.37, p.S59-S59

2001

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial

European journal of cancer (1990), 1999-09, Vol.35, p.S247-S247

1999

Link zum Volltext

Verfügbarkeit prüfen

HLA-A and B antigens and pulmonary tuberculosis in greeks

British journal of diseases of the chest, 1987, Vol.81 (2), p.147-149

1987

Link zum Volltext

Verfügbarkeit prüfen

HLA typing in the Hong Kong Chest Service/British Medical Research Council Study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions

The American review of respiratory disease, 1989-09, Vol.140 (3), p.854

1989

Link zum Volltext

Verfügbarkeit prüfen

HLA antigens and otosclerosis. A possible new genetic factor

Archives of otolaryngology (1960), 1982-12, Vol.108 (12), p.769

1982

Link zum Volltext

Verfügbarkeit prüfen

HLA antigens and congenital dislocation of the hip

Tissue antigens, 1983-10, Vol.22 (4), p.295-297

1983

Link zum Volltext

Verfügbarkeit prüfen

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(15)

Sprache

Englisch
(15)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial

Alternate Paclitaxel-Gemcitabine and Paclitaxel-Vinorelbine Biweekly Administration in Non-small Cell Lung Cancer Patients: a Phase II Study

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

Moxifloxacin Monotherapy Is Effective in Hospitalized Patients with Community-Acquired Pneumonia: The MOTIV Study—A Randomized Clinical Trial

6599 POSTER Comparison of cisplatin–paclitaxel combination versus cisplatinetoposide as first line chemotherapy in SCLC

Alternative administration of paclitaxel-gemcitabine and paclitaxel-vinorelbine as first line treatment in NSCLC patients. A phase II study

HLA antigens in diabetics with calcified shoulder periarthritis (CSP)

The sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study

Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial

HLA-A and B antigens and pulmonary tuberculosis in greeks

HLA typing in the Hong Kong Chest Service/British Medical Research Council Study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions

HLA antigens and otosclerosis. A possible new genetic factor

HLA antigens and congenital dislocation of the hip

Suchergebnisse filtern